BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA ...
No significant safety or dose limiting toxicities have been reported BOSTON, March 27, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more ...
TransCode Therapeutics (NASDAQ:RNAZ) announces to raise $10M through the purchase and sale of 10.25M shares of its common stock and warrants to purchase up to 10.25M shares of common stock priced ...
11don MSN
The Pentagon has restored some webpages highlighting the wartime contributions of Navajo Code Talkers and other Native ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an RNA oncology company with a current market capitalization of $12.21 million, has announced the initiation of dosing the first patient in ...
(RTTNews) - TransCode Therapeutics, Inc. (RNAZ) Monday has entered an agreement to sell 10.25 million shares of common stock and an equal number of warrants at $0.98 per unit, in compliance with ...
TransCode's 2023 Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic activity, even at a microdose of the drug ...
The Pentagon restored some webpages highlighting the crucial wartime contributions of Navajo Code Talkers and other Native American veterans on Wednesday, days after tribes condemned the action ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback